AFLIBERCEPT
Information current as at: 1 April 2025
PBAC meeting date: July 2025
Submission Details
- Brand name:
-
- Afqlir® Enzeevu™
- Pharmaceutical company:
- SANDOZ PTY LTD
- Condition/indication:
(therapeutic use) -
- Macular oedema secondary to retinal vein occlusion (RVO) Diabetic macular oedema (DMO) Subfoveal choroidal neovascularisation (CNV) secondary to age-related macular degeneration (AMD)
- PBAC Submission type:
- New PBS listing (–)
- Comment:
- --
- Related medicines:
- --
Progress Details
-
Submission received for: - July 2025 PBAC meeting
-
2Opportunity for consumer comment:
- Open 02/04/2025 and close 28/05/2025 (see PBS Website)
-
3PBAC meeting:
- Has not yet occurred
-
4PBAC outcome published:
- Has not yet commenced
-
5Lodgement of required documentation:
-
6Agreement to listing arrangements:
- Has not yet commenced
-
7Government processes:
- Has not yet commenced
-
8Medicine listed on the PBS:
- Has not yet occurred
Case ID: a1046
Page last updated: 02 April 2025